

bjcclub breast
Journal
Club

L'IMPORTANZA DELLA RICERCA IN ONCOLOGIA

**20 - 21 APRILE
2023 ROMA**

THE HIVE HOTEL

Via Torino, 6

**THE
OXFORD DEBATE
EDITION**

La malattia oligometastatica: evidenze e trial in corso, raccomandazioni

Analisi paper su definizione malattia oligometastatica

Prof. ICRO MEATTINI, MD

Department of Experimental and Clinical Biomedical Sciences “M. Serio”, University of Florence
Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero-Universitaria Careggi

Florence, Italy

icro.meattini@unifi.it

DISCLOSURE INFORMATION

Icro Meattini outside the present work received occasional small fee honoraria for advisory role from Novartis, Eli Lilly, Pfizer, Accuray, Seagen, Gilead.



UNIVERSITÀ
DEGLI STUDI
FIRENZE



Azienda
Ospedaliero
Universitaria
Careggi




Associazione
Italiana
Radioterapia
Oncologica

ESTRO

Oligometastases – Definitions and concepts

- Introduced for the first time in 1995
- Commonly used to describe an **intermediate state of cancer spread between localized disease and widespread metastases**
- Patients show only a limited number or regions involved
- No more than five total lesions

Hellman S, Weichselbaum RR. J Clin Oncol 1995
Weichselbaum RR, Hellman S. Nat Rev Clin Oncol 2011



Oligometastases

Characterization and Classification

Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation




Matthias Guckenberger, Yolande Lievens, Angélique B Bouma, Laurence Collette, Andre Dekker, Nandita M deSouza, Anne-Marie C Dingemans, Beatrice Fournier, Coen Hurkmans, Frédéric E Lecouvet, Icro Meattini, Alejandra Méndez Romero, Umberto Ricardi, Nicola S Russell, Daniel H Schanne, Marta Scorsetti, Bertrand Tombal, Dirk Verellen, Christine Verfaillie, Piet Ost

Guckenberger M, et al. Lancet Oncol 2020

Oligometastases – Characterization and Classification


Q4: Is the patient under active systemic therapy at the time of oligometastatic disease diagnosis?



Guckenberger M, et al. Lancet Oncol 2020

Oligometastases – Characterization and Classification


Q5: Are any oligometastatic lesions progressive on current imaging?




Guckenberger M, et al. Lancet Oncol 2020

Oligometastases – Characterization and Classification

Dynamic oligometastatic state model



Guckenberger M, et al. Lancet Oncol 2020



Adapted from **Punglia RS, et al.** N Engl J Med 2007

Contribution of improved locoregional control to survival depends on the effectiveness of systemic treatment and viceversa

Oligometastases – Definitions and concepts

Cancer Treatment Reviews 110 (2022) 102462



ELSEVIER

Contents lists available at [ScienceDirect](#)

Cancer Treatment Reviews

journal homepage: www.elsevier.com/locate/ctrv

Hot Topic

Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?

Federica Miglietta^{a,b}, Luca Visani^c, Sabrina Marini^{a,b}, Gaia Griguolo^{a,b}, Grazia Maria Vernaci^{a,b}, Michele Bottosso^{a,b}, Maria Vittoria Dieci^{a,b}, Icro Meattini^{c,d}, Valentina Guarneri^{a,b,*}

^a Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy


^b Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy

^c Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy

^d Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy


Miglietta F, et al. Cancer Treat Rev 2023

Oligometastases – Definitions and concepts




Miglietta F, et al. Cancer Treat Rev 2023

Oligometastases – Definitions and concepts




Miglietta F, et al. Cancer Treat Rev 2023

Oligometastases – Definitions and concepts



Miglietta F, et al. Cancer Treat Rev 2023

Radiation and New Drugs




Nature Reviews | Clinical Oncology

Sharma RA, et al. Reviews Clinical Oncology 2016

Radiation and New Drugs

Concept of therapeutic index

Increasing the effective ionizing radiation dose by just 10% will increase tumor control rates by 5–30%



Sharma RA, et al. Reviews Clinical Oncology 2016

Recommendations on integration of radiation therapy with targeted treatments for breast cancer consensus


Florence, Italy – June 16-17 – Hotel Mediterraneo




















Recommendations on integration of radiation therapy with targeted treatments for breast cancer consensus meeting

Florence (IT), 16-17th June 2023

Grand Hotel Mediterraneo, Lungarno del Tempio, 44

Endorsed by



 <p>Carlotta Becherini Florence, Italy</p> <p>BIO</p>	 <p>Saverio Caini Florence, Italy</p> <p>BIO</p>	 <p>Charlotte Coles Cambridge, UK</p> <p>BIO</p>	 <p>Javier Cortes Barcelona, Spain</p> <p>BIO</p>	 <p>Icro Meattini Florence, Italy</p> <p>BIO</p>	 <p>Andrea Morandi Florence, Italy</p> <p>BIO</p>	 <p>Birgitte Offersen Aarhus, Denmark</p> <p>BIO</p>	 <p>Philip Poortmans Antwerp, Belgium</p> <p>BIO</p>
 <p>Giuseppe Curigliano Milan, Italy</p> <p>BIO</p>	 <p>Evandro de Azambuja Brussels, Belgium</p> <p>BIO</p>	 <p>Nadia Harbeck Munich, Germany</p> <p>BIO</p>	 <p>Clare Isacke London, UK</p> <p>BIO</p>	 <p>Hope Rugo San Francisco, USA</p> <p>BIO</p>	 <p>Viola Salvestrini Florence, Italy</p> <p>BIO</p>	 <p>Luca Visani Florence, Italy</p> <p>BIO</p>	
 <p>Orit Kaidar-Person Sheba Tel Hashomer, Israel</p> <p>BIO</p>	 <p>Matteo Lambertini Genoa, Italy</p> <p>BIO</p>	 <p>Lorenzo Livi Florence, Italy</p> <p>BIO</p>	 <p>Elisabetta Marangoni Paris, France</p> <p>BIO</p>				

Register at



<https://clinicaloncology.events/>

La malattia oligometastatica: evidenze e trial in corso, raccomandazioni

Analisi paper su definizione malattia oligometastatica

Prof. ICRO MEATTINI, MD

Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence
Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero-Universitaria Careggi
Florence, Italy

Contact at icro.meattini@unifi.it

Twitter Account
@Icro_Meattini



UNIVERSITÀ
DEGLI STUDI
FIRENZE



Azienda
Ospedaliero
Universitaria
Careggi



Associazione
Italiana
Radioterapia
Oncologica

ESTRO